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The nuclear export inhibitor leptomycin B (LMB) prevents the export of proteins from the nucleus to the cytoplasm, protects p53
from Mdm2-mediated degradation and is a very potent inducer of the p53 transcriptional activity. Here we suggest that LMB can also
interfere with the degradation of human Mdm2. In the presence of this drug, we observed two novel forms of this protein: a slow
mobility form and an amino-terminal fragment with an apparent molecular mass of 32kDa. The presence of this 32kDa band is
abolished with proteasome inhibitors, indicating that its appearance could be because of limited processing by the proteasome. These
results may be useful in understanding the mechanism of degradation of Mdm2 by the proteasome.
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It is well established that approximately 50% of human tumours
carry inactivating mutations in the p53 gene (reviewed in Hollstein
et al, 1999). In many others, the p53 tumour suppressor function is
hampered by the overexpression or inactivation of cellular factors
that regulate the levels and activity of p53 or by the expression of
certain oncoviral proteins (reviewed in Lane and Lain, 2002;
Vousden, 2002). Radiotherapy and many of the chemotherapeutic
drugs currently used in cancer treatment are potent inducers of the
p53 response. Furthermore, a lack of response to these treatments
has been frequently associated with mutations in the p53 gene
(Pirollo et al, 2000; Soussi, 2000). These observations suggest that
the activation of p53 is a key determinant for the success of a
treatment. However, although effective in many cases, most of the
available treatments have a serious disadvantage, namely their
DNA-damaging effects, which in the long term may lead to the
appearance of secondary tumours. Therefore, the search for novel
nongenotoxic activators of the p53 response is widely thought to
be essential in improving the treatment of those cancers in which
the p53 function is not abolished by mutation.
We have previously shown that the Streptomyces sp. metabolite
leptomycin B (LMB) induces the transcriptional activity of a p53-
dependent reporter plasmid (Lain et al, 1999a). This effect of LMB
is accompanied by an increase in the levels of the products of two
p53-dependent genes, p21 and Mdm2 (Freedman and Levine, 1998;
Lain et al, 1999a) in a p53-dependent manner (Smart et al, 1999).
As presented here, the increase in the levels of these proteins is
accompanied by an increase in the levels of their messenger RNAs
(Figure 1A), firmly establishing that LMB induces the transcrip-
tional activity of p53 and that this occurs without an increase in
the levels of p53 mRNA expression (Figure 1B). We also show that
the induction of a p53 reporter construct can occur at less than
nanomolar concentrations of LMB (Figure 1B), demonstrating the
potency of LMB as an inducer of the p53-dependent transcrip-
tional activity.
Accordingly, we have previously reported that LMB has a strong
killing effect on cell lines derived from neuroblastomas at
nanomolar concentrations in a p53-dependent way, whereas it
has only a relatively mild and reversible growth arresting effect on
normal human fibroblasts in culture at micromolar concentrations
(Smart et al, 1999).
In the early reports, LMB was shown to have antitumour
effects in mouse xenograft models (Roberts et al, 1986) that led to
a phase I trial (Newlands et al, 1996). Unfortunately, these studies
had to be stopped because of the malaise and anorexia induced by
the drug when administered systemically by intravenous injection.
We then thought that LMB may be of use in the prevention of
tumours, such as HPV-associated cervical carcinomas, that can be
treated locally and that tend to be recurrent after surgery. This
drug increased the stability and the transcriptional activity of p53
in cell lines derived from cervical cancers and effectively induced
cell death in a p53-dependent way (Hietanen et al, 2000).
These results, together with the potency of LMB in inducing the
transcriptional activity of p53, imply that the elucidation of the
mechanism of action of LMB is of great importance, and may make
it possible to define new ways to target the p53 pathway that yield
effective nongenotoxic drugs.
LMB is thought to function primarily as an inhibitor of the
export of proteins from the nucleus to the cytoplasm because of its
ability to interact with and impair the function of the nuclear
export factor crm-1 (Kudo et al, 1999). Although other effects of
LMB that could lead to a DNA damage response cannot be
excluded, LMB is likely to be a very potent inducer of the p53
response, which does not act directly through the DNA damage
pathway (Lain et al, 1999b).
Middeler et al (1997) have elegantly demonstrated that p53
shuttles from the nucleus to the cytoplasm. Additionally, p53 was
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sshown to contain two nuclear export sequences, one in its
oligomerisation domain (Stommel et al, 1999) and the other in
its N-terminus (Zhang and Xiong, 2001), which probably explains
its sensitivity to LMB. Direct interaction of p53 with crm-1 has not
been reported yet.
In normal nonstressed cells, p53 has a very short half-life
because of the following autoregulatory feedback loop mechanism
in which the Mdm2 protein plays a key role. It has been well
established that wild-type p53 acts as a transcriptional activator of
the Mdm2 gene (Barak et al, 1993). In turn, Mdm2, which
itself has a very short half-life because of its autoubiquitination
activity (Fang et al, 2000), has the ability to interact with
p53 and to function as an E3 ubiquitin ligase that promotes
the conjugation of p53 to ubiquitin (Honda et al, 1997;
Fang et al, 2000; Honda and Yasuda, 2000). This conjugation
serves as a tag that effectively targets p53 for degradation by the
proteasome (Haupt et al, 1997; Kubbutat et al, 1997). We have
previously shown that LMB protects p53 from Mdm2-mediated
ubiquitination and degradation (Lain et al, 1999a; Xirodimas et al,
2001b). Here, we have asked whether LMB has any effects on
Mdm2.
MATERIALS AND METHODS
Cells and culture conditions
U2OS cells (expressing wild-type p53) and H1299 cells (p53-
negative) were obtained from the ATCC. The T22 RGCDfos-lac Z
cell line and the human normal primary fibroblasts (HNF) were
described in Lu et al (1996) and Lain et al (1999a), respectively.
Cells were cultured in RPMI (H1299) or DMEM (U2OS, T22Dfos-
lac Z and HNF) supplemented with 10% foetal calf serum and
gentamycin antibiotic at 371C in an atmosphere containing 5%
CO2.
Chemicals and reagents
Leptomycin B was obtained from Novartis. Actinomycin D was
obtained from Sigma. Stock solutions were prepared in absolute
ethanol. Proteasome inhibitors (MG132, lactacystin, ALLN, epox-
omycin and PI-II) and calpain inhibitors (ALLM and Z-Val-Phe-
CHO) were obtained from Calbiochem, and stock solutions were
prepared in DMSO.
Plasmids
pCMVhMdm2 and pCMVhMdm2mtNLS were a kind gift from Dr
A Levine. hMdm2mtNoLS and the expression vector for p14ARF
(pcDNA3p14ARF) were provided by K Vousden. pcDNA3Mdm2
(1–244) and pcDNA3Mdm2(1–258) were described by Midgley
et al (2000). pCMVhMdm2C462A as well as all other point mutants
of hMdm2 were obtained by site-directed mutagenesis. The
expression vector for the N-terminal fragment of hMdm2
(pCMVhMdm2(1–244)) was derived from pCMVhMdm2 by
insertion of a translation terminator at codon 245.
pCOCMdm22 was a gift from M Oren. pcDNA3p53 is described
in Xirodimas et al (2001a). pSVp14ARF was obtained by inserting
the NcoI–XbaI fragment of pcDNA3p14ARF into the SacI and XbaI
sites of the pSV vector.
Antibodies
p53 was detected using the DO1 mouse monoclonal antibody
(Stephen et al, 1995). Human Mdm2 was detected using the 4B2,
3G5, SMP14, 2A9, 2A10 and 4B11 mouse monoclonal antibodies
(Chen et al, 1993; Picksley et al, 1994).
Northern and b-gal reporter assays
Total RNA was obtained from normal human primary fibroblasts
and mRNA levels were analysed as described by Hietanen et al
(2000).
T22RGCDfos-lac Z cells were seeded at a density of 10
4 cells per
well in 96-well plates. After 24h recovery time, LMB or control
drugs were added and cells were incubated with the drugs for 16h.
Cells were lysed in Promega reporter lysis buffer for 1h, and then in-
cubated with CPRG b-gal substrate (Boehringer–Mannheim,
Ingelheim, Germany). Colour density was measured at 590nm using
a Dynatech plate reader.
Figure 1 (A) LMB increases the levels of Mdm2 and p21 mRNAs. Total
RNA was prepared from untreated or LMB-treated human normal primary
fibroblasts and the hMdm2, p21 and p53 mRNAs were detected by
Northern blotting. GAPDH mRNA was analysed as a control. (B) T22
RGCDfos-lac Z cells were treated with the indicated concentrations of
LMB for 18 h and p53-dependent b-gal reporter activity was measured.
Figure 2 LMB induces the appearance of novel forms of hMdm2. (A)
H1299 cells were transfected with an expression vector for hMdm2
(pCMVhMdm2) and left untreated (lane 1) or treated with 2nM LMB for
18h (lane 2). Cell extracts were analysed by Western blotting and hMdm2
was detected using the 4B2 mouse monoclonal antibody against the amino-
terminus of the protein. The positions of the bands corresponding to the
full-length hMdm2, the LMB-induced slower mobility form and the 32kDa
fragment are indicated by arrows. (B) LMB does not affect hMdm2
ubiquitination in vivo. H1299 cells were transfected with 5mg pCMVhMdm2
and 2mg pCMVHis6–Ubiquitin. In lanes 1 and 3, cells were left untreated, in
lanes 2 and 4 they were treated with 2nM LMB and in lanes 3 and 6, they
were also cotransfected with 5mg of the pcDNA3p14ARF expression
vector. In lanes 1–3, total hMdm2 was analysed and in lanes 4–6, His6–
ubiquitin complexes were isolated and ubiquitinated hMdm2 was detected
using 4B2.
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sU2OS cells were seeded in 24-well plates and transfected with
60ng of the RGCDFos-lacZ p53 reporter plasmid, 60ng of the
control SV-promoter-dependent luciferase reporter and the
indicated plasmids expressing hMdm2(1–244) or p14ARF using
the Fugene protocol as described by Midgley et al (2000). Cells
were harvested 48h after transfection. b-gal activity was measured
as above and luciferase activity was analysed using the
Dual-Luciferase
s Reporter Assay System (Promega,
Southampton, UK), a MicroLumat LB96V(EG&G Berthold)
luminometer.
Western blot analysis
Cells were seeded in 10cm dishes at a density of 910
5 cells per
well and transfected using the calcium phosphate method.
Equivalent amounts of CMV promoter in the transfections
were maintained with the pcDNA3 control vector. The
amount of plasmid used in each transfection was topped
up to 20mg with the bacterial plasmid Bluescript. After a 24h
recovery period, 2nM LMB and the indicated amounts of
proteasome inhibitors were added to the cells for 18h before
harvesting. Cell lysates were prepared using the NP40 buffer
described by Xirodimas et al (2001a) or by direct lysis in SDS–
PAGE loading buffer. Equivalent results were obtained with both
the methods. Samples were analysed in 4–12% Novex gels using
MOPS running buffer after which they were transferred to
Immobilon membranes that were incubated with the indicated
primary antibodies and developed as described by Xirodimas et al
(2001a).
Purification of His-tagged ubiquitin conjugates
For the in vivo ubiquitination assay, vectors expressing the
relevant proteins were cotransfected with 2mg of the vector
encoding His-tagged ubiquitin. Purification of His6-ubiquitinated
conjugates was performed as described in Xirodimas et al (2001a).
His-ubiquitin tagged hMdm2 was analysed by Western blot
analysis with 4B2 antibody.
RESULTS
LMB induces the appearance of two novel forms of hMdm2
Mdm2 has been described to shuttle between the nucleus and the
cytoplasm and to contain a crm1-binding nuclear export sequence
(Roth et al, 1998). Accordingly, Argentini et al (2001) found that
LMB partly decreases the export of Mdm2 from the nucleus using
heterokaryon assays. However, this is not reflected by any
convincing changes in the localisation of Mdm2 in the presence
Figure 3 The appearance of the 32kDa is a post-transcriptional event and is prevented by proteasome inhibitors. (A) H1299 cells were transfected with
vectors expressing either wild-type hMdm2 lanes (1–3), hMdm2mtNLS lanes (4–6) or hMdm2mtNoLS lanes (7–9). In lanes 1, 4 and 7, cells were left
untreated. In lanes 2, 5 and 8, they were treated with LMB, in lanes 3, 6 and 9, they were treated for 3 h with the proteasome inhibitor MG132 (20mM). Cells
were harvested and hMdm2 was detected by Western blotting as above. The positions of the bands corresponding to the full-length hMdm2 and the 32kDa
fragment are indicated by arrows. (B) H1299 cells were transfected with an expression vector for hMdm2 or the hMdm2C462A mutant and treated with
2n M leptomycin B for 18 h. hMdm2 was detected as above. (C) H1299 cells were transfected with 5mg of the expression vector for hMdm2
(pCMVhMdm2) and treated with 2nM leptomycin B alone for 18 h (lanes 1, 3, 5, 7 and 11) or together with 20mM MG132 (lane 2), 20mM PI-II (lane 4) or
20mM lactacystin (lane 6), 4mM epoxomycin (lane 8), 10mM Z-Val-Phe-CHO (lane 9) or 10mM ALLM (lane 10). Cell extracts were analysed by Western
blotting and hMdm2 was detected using 4B2. The positions of the bands corresponding to the full-length hMdm2 and the 32kDa fragment are indicated by
arrows on the left side.
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sof LMB by either immunocytofluorescence or cell fractionation
experiments (data not shown). Instead, we observed that LMB
induces the appearance of a shorter human Mdm2 (hMdm2)
product of approximately 32kDa, which reacts with the 4B2 mouse
monoclonal antibody directed against the amino terminus of the
protein (Chen et al, 1993). Other insults that are known to activate
p53, such as actinomycin D and UVC, did not cause the
appearance of this product (not shown). In many experiments,
we could also detect that the presence of the 32kDa band is
accompanied by the appearance of another modified form of
hMdm2 with a slightly slower electrophoretic mobility than full-
length hMdm2 in nontreated cells. As shown in the in vivo
ubiquitination assay presented in Figure 2B, unlike proteasome
inhibitors and the p14ARF tumour suppressor (Xirodimas et al,
2001a), LMB did not increase the levels of ubiquitin-conjugated
hMdm2 and the 32kDa band did not appear to be bound to
ubiquitin.
The appearance of the 32kDa band in the presence of LMB
is suppressed by proteasome inhibitors
As shown in Figure 3A, LMB did not effectively induce the
appearance of the 32kDa band in cells transfected with a human
Mdm2 with mutations in its nuclear localisation signal at residues
181–185 (hMdm2mtNLS) (Tao and Levine, 1999), or in its
nucleolar localisation signal (hMdm2mtNoLS) that is located
between residues 466 and 473 (Lohrum et al, 2000). This result has
two consequences. First, it establishes that the appearance of the
32kDa band is due to an effect on the Mdm2 protein and not to an
effect of LMB on the expression of the transfected vector. Second,
it could suggest that the appearance of the 32kDa band requires
that hMdm2 reaches the nuclear and nucleolar comparments
efficiently.
In subsequent experiments, we aimed to characterise the activity
responsible for the accumulation of the 32kDa band in the
presence of LMB. Mdm2 has been previously described to be
susceptible to caspase cleavage, producing a band of approxi-
mately 60kDa (Pochampally et al, 1999). However, the levels of the
32kDa band detected with LMB were not decreased by preincuba-
tion with caspase inhibitors (not shown). Instead, we observed that
the ratio between the levels of full-length hMdm2 and the 32kDa
product significantly decreased when an hMdm2 variant with a
point mutation in its RING finger domain (hMdm2C462A), and
therefore deficient for autoubiquitination and degradation (Honda
et al, 1997), was analysed (Figure 3B). This suggested that the
appearance of the 32kDa fragment could be to some extent
dependent on ubiquitination status of Mdm2 and therefore,
potentially because of a proteasome-associated proteolytic activity.
As presented in Figure 3C (lanes 2 and 4), the proteasome
inhibitors MG132 and PI-II (Z-LeuLeuPhe-CHO) significantly
decreased the appearance of the 32kDa fragment in the presence
of LMB. This effect is also observed with the more specific
inhibitors of the proteasome activity lactacystin and epoxomycin
(Figure 3C, lanes 6 and 8), but not with the calpain inhibitors Z-
Val-Phe-CHO and ALLM (Figure 3C, lanes 9 and 10). These results
suggest that the appearance of the 32kDa fragment may depend on
the activity of the proteasome. The band that appears below the
64kDa marker after long-term incubation with proteasome
inhibitors (Figure 3C) and with the hMdm2C462A mutant
(Figure 3B) could be related to the caspase-dependent cleavage
(Pochampally et al, 1999).
The cleavage did not seem to be because of an induction of a
proteolytic activity, since the presence of the 32kDa fragment was
never accompanied by a decrease in the levels of full-length
hMdm2 (Figure 2A, B, 3A, and 5A, B). This suggested that LMB
could increase the stability of this fragment. However, we observed
that the 32kDa band is very stable (Figure 4A, B), and that it was
not significantly destabilised after removal of LMB from the
medium (Figure 4C).
Mapping of the cleavage site generating the N-terminal
32kDa fragment
As shown in Figure 5A, the 32kDa fragment detected in the
presence of LMB contains epitopes 4B2, 3G5, SMP14 and 2A9
reacting with the amino-terminal half of Mdm2 (Chen et al, 1993;
Picksley et al, 1994). Instead, the 2A10 and 4B11 antibodies, that
react with the C-terminus of Mdm2 (Chen et al, 1993) do not
recognise the 32kDa band (Figure 5B). We have not been able to
find the C-terminal fragment resulting from this cleavage with any
of these two antibodies. Several additional bands were obtained
with the C-terminal antibodies 2A10 and 4B11 (Figure 5B);
however, these bands also appear in cells not overexpressing
hMdm2 (not shown) and independent of the presence of LMB
(Figure 5B).
Figure 4 Analysis of the stability of hMdm2 in the presence of LMB. (A)
H1299 cells were transfected with the expression vector for hMdm2 and
left untreated (lanes 1–4) or pretreated with 2nM LMB for 18 h (lanes 5–
8). After this time, 10mgml
1 cyclohexamide (CHX) was added to the
medium and the cells were harvested after 0, 10, 20 and 40min. Cell
extracts were analysed by Western blotting and hMdm2 was detected
using 4B2. The positions of the bands corresponding to the full-length
hMdm2 and the 32kDa fragment are indicated by arrows. (B) H1299 cells
were transfected with the expression vector for hMdm2 and pretreated
with 2nM LMB for 18h. After this time, the medium was removed and
replaced with a medium containing 10mgml
1 CHX (lanes 1–4) or a
medium containing 10mgml
1 CHX and 2nM LMB (lanes 5–8). Cells were
harvested after 0, 1.5, 3 and 6 h and cell extracts were analysed by Western
blotting and hMdm2 was detected using 4B2. (C) H1299 cells were
transfected with the expression vector for hMdm2 and pretreated with
2n M LMB for 18h after which 10mgml
1 CHX was added for 4h. At this
time, virtually all detected hMdm2 has an apparent molecular weight of
32kDa. In order to see whether removal of LMB destabilised the 32kDa
fragment, we removed the medium and replaced it with a medium
containing 10mgml
1 CHX only (lane 1) or a medium containing
10mgml
1 CHX and 2nM LMB (lane 2). After 5 more h, cells were
harvested and analysed as above.
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sUsing a series of deletion mutants of murine Mdm2 (Midgley
et al, 2000), we were able to roughly map the region containing the
C-terminus of this 32kDa N-terminal fragment of Mdm2
(Figure 5C). According to this measurement, the C-terminus of
this fragment is located approximately within amino 245 and 272
of human Mdm2. The 2A10 antibody has been shown to recognise
two epitopes in Mdm2: one between positions 255 and 260, and a
C-terminal epitope at positions 388 and 392. The lack of 2A10
reactivity of the 32kDa fragment allowed us to map the C-terminus
of the 32kDa fragment more accurately to a region between
residues 245 to approximately 260. Interestingly, this region is
contained within a a region that is bound by the p14ARF tumour
suppressor (Midgley et al, 2000; Bothner et al, 2001) (Figure 5E).
However, we have not been able to show that p14ARF over-
expression affects the levels of the 32kDa LMB-induced band (not
shown).
We then proceeded to substitute the amino acids in this region
by alanine using site-directed mutagenesis. Residues 245, 246, 247,
248, 249, 250, 251, 252, 253, 254, 255, 256, 259, 260 and 261
were substituted. Despite our efforts, we have not been able to
identify a specific residue required for this cleavage
event. However, a fortuitous mutation allowed us to map the
cleavage site more accurately. When introducing a point mutation
at position 254, an open reading frame encoding a frame
shift mutant of hMdm2 was obtained. This mutant finished at
position 252 of the hMdm2 sequence and had 47 extra residues at
its C-terminus encoded by an alternative reading frame
(hMdm2(1–252N47)). When cells expressing this mutant were
treated with LMB, the 32kDa band still appeared (Figure 5D). This
indicates that the C-terminus of the 32kDa band is before or at
position 252.
An N-terminal fragment consisting of residues 1–244 from
hMdm2 can protect p53 from degradation by Mdm2
To study the significance of this 32kDa fragment for p53
stabilisation and activity, we created an expression vector for an
hMdm2 deletion mutant that contains the first 244 amino acids
Figure 5 Mapping of the 32kDa band C-terminal region. (A and B) H1299 cells were transfected with an expression vector for hMdm2 (pCMVhMdm2)
and left untreated () or treated with 2nM LMB for 18 h (+). Cell extracts were analysed by Western blotting and hMdm2 was detected using the mouse
monoclonal antibodies 2A9, 4B2, SMP14 and 2A9 (A), or 4B2, 4B11 and 2A10. (B). The positions of the bands corresponding to the full-length hMdm2 and
the 32kDa fragment are indicated by arrows. (C) H1299 cells were transfected with an expression vector for hMdm2 (pCMVhMdm2) (lane1), a vector
expressing residues 1–244 of murine Mdm2 (pcDNA3Mdm2 1–244) or a vector expressing residues 1–258 (pcDNA3Mdm2 1–258) (lane3).
pcDNA3Mdm2 1–244 and pcDNA3Mdm2 1–258 contain six and 14 additional residues at their C-terminus, respectively. (D) H1299 cells were
transfected with expression vectors for hMdm2(1–252N47) (lanes 1 and 2) or hMdm2 (lanes 3 and 4). In lanes 2 and 3, cells were treated with 2nM LMB for
18h. Cell extracts were analysed by Western blotting and developed with the 4B2 antibody. The position of the 32kDa band is indicated with an arrow. In
lane 5, cells were transfected with the plasmid encoding the hMdm2 (1–244) mutant. This fragment is expressed at very high levels, and therefore, a shorter
exposure of the gel is shown for this lane. (E) Sequence of the acidic domain in hMdm2. The regions involved in the interaction with the amino-terminus of
p14ARF according to Bothner et al (2001) and the 2A10 epitope are underlined. The region proposed to contain the C-terminus of the 32kDa band is
marked with a discontinuous line.
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sfrom the N-terminus (pCMVhMdm2(1–244)) (Figure 5D, lane 5).
This deletion mutant was able to protect p53 from degradation by
full-length murine Mdm2 (Figure 6A), possibly by competing with
Mdm2 for its interaction with p53. This fragment of hMdm2
contains the region necessary for binding to p53 and binding of
Mdm2 to p53 is thought to be sufficient to inactivate the
transcriptional activity of p53 (Chen et al, 1996). Therefore, as
could be expected, this deletion mutant could not induce the
transcriptional activity of p53 (Figure 6B). This lack of activation
was not because of a toxic effect of the pCMVhMdm2 (1–244)
vector as indicated by the analysis of the control luciferase reporter
activity, where hMdm2 (1–244) expression significantly increases
this activity.
DISCUSSION
We have shown that the electrophoretic behaviour of hMdm2 is
altered significantly in the presence of the nuclear export inhibitor
LMB. LMB induces the appearance of two novel hMdm2 products,
namely a band migrating slightly slower than the major hMdm2
band in the absence of drug, and a product with an apparent
molecular weight of 32kDa, containing epitopes from the N-
terminal part of hMdm2. The C-terminus of this fragment maps
between residues 245 and 252 of hMdm2.
The 32kDa N-terminal fragment of hMdm2 may have some
relevance for the observed stabilisation of p53 by LMB as
evidenced by the ability of transfected truncated hMdm2 to
protect p53 from Mdm2-mediated degradation, possibly by acting
as a dominant negative towards Mdm2. However, although LMB
protects p53 from murine Mdm2-mediated ubiquitination and
degradation (Xirodimas et al, 2001b), the corresponding 32kDa
form of murine Mdm2 has never been detected. Therefore,
although the accumulation of the 32kDa fragment may contribute
to the stabilisation of p53 by LMB, it is not indispensable.
Additionally, the induction of the accumulation of the 32kDa
cleavage product of hMdm2 is not likely to contribute to the potent
activation of p53-dependent transcription by LMB, since a similar
fragment does not increase, but rather decreases, p53 activity in a
transcriptional reporter system. One possibility is that the
accumulation of the 32kDa fragment negatively modulates the
p53 transcriptional activity and contributes to diminishing the
cytotoxic effects of LMB.
The appearance of the 32kDa fragment occurs without
significant decrease in the level of full-length hMdm2. However,
this does not seem to be because of alterations in the expression of
ectopic hMdm2 cDNA, since different small mutations at distant
sites of the protein (the NLS and the NoLS) prevent the detection
of the 32kDa band. The levels of the 32kDa band did not seem to
be related to the nuclear export signal in hMdm2 proposed by Roth
et al (1998), since this band also appeared when cells transfected
with a mutant for this putative nuclear export signal were treated
with LMB (not shown).
Inhibition of crm1-mediated nuclear export by LMB could alter
some event in the degradation of hMdm2 by the proteasome,
allowing an amino-terminal product to accumulate when it would
not otherwise do so. Supporting this hypothesis, we have shown
that the appearance of the 32kDa band is clearly prevented by
several proteasome inhibitors. Although it is possible that
proteasome inhibitors, and even lactacystin, may be affecting
other proteolytic activities in addition to that of the proteasome
(Ostrowska et al, 2000), given the diversity of proteasome
inhibitors having the same effect, it is unlikely that the appearance
of the 32kDa fragment is not because of limited proteolysis by the
proteasome.
We have shown that the 32kDa band corresponds to the amino-
terminal half of the protein and we have determined that the C-
terminus of the 32kDa band lies within residues 245 to
approximately 252 of the hMdm2 sequence. However, extensive
point mutagenesis of this region did not abolish the proteolytic
event. It is interesting to note that in the case of the NFkB
p105 precursor, which is known to be susceptible to partial
proteasome-mediated proteolysis to generate the p50 active
fragment (Palombella et al, 1994), it has not been
possible to precisely map the cleavage site. This indicates that
the cleavage of hMdm2 and p105 are not sequence dependent, but
may rely on recognition of a structural feature. In the case of
Figure 6 The 1–244 fragment of hMdm2 protects p53 from Mdm2-
mediated degradation, but does not increase the transcriptional activity of
p53. (A) H1299 cells were transfected as described with 2mgo f
pcDNA3p53 and 2mg of pCOCMdm22 (lane 1), 2mg of pcDNA3p53
(lane 2), 2mg of pcDNA3p53, 2mg of pCOCMdm22 and 15mgo f
pCMVhMdm2 (1–244) (lane 3), or 2mg of pcDNA3p53, 2mgo f
pCOCMdm22 and 7.5mg of pCMVhMdm2 (1–244) 1mg (lane 4).
Cells were analysed by Western blotting using the DO1 antibody against
p53 (upper panel). hMdm2 (1–244) was detected using the 4B2 antibody
against Mdm2 (lower panel). (B) U2OS cells, which contain endogenous
wild-type p53, were transfected with the p53-dependent RGCDFos-lacZ
and the SV-luciferase reporter plasmids together with either 0.25mg
pcDNA3 control vector, 0.25mg pCMVhMdm2 (1–244) or 0.025mg
pSVp14ARF. p53-dependent b-gal and control SV40 early promoter-driven
luciferase reporter activities were measured. The average and the s.d. of
four transfections with each set of constructs is shown.
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sNFkB, a glycine-rich region (GRR) between positions 375 and 401
has been shown to be involved in the generation of the p50 form
that is thought to occur at approximately position 433 (Lin and
Ghosh, 1996). No similar GRR can be found in the hMdm2
sequence.
The cleavage site that would generate the 32kDa band maps to a
conserved and unstructured region in hMdm2 rich in acidic
residues and serines (Bothner et al, 2001). There is also data
showing that this acidic domain is important for the stability of
Mdm2. As reported by Argentini et al (2001), deletion of the acidic
domain (residues 222–272) increases the stability of the protein
without decreasing its ubiquitination. Additionally, the interaction
site for the amino terminus of p14ARF, which is necessary for
p14ARF to increase the levels of Mdm2 and its ubiquitinated forms
(Xirodimas et al, 2001a), is also in this acidic region (Midgley et al,
2000; Bothner et al, 2001). PEST sequences are conformationally
flexible regions that do not show a high conservation of exact
sequence, but contain a high proportion of proline (P), glutamate
(E), serine (S) and threonine (T). This type of sequence is
considered to target proteins for degradation by the proteasome
and possibly other proteolytic systems (Rechsteiner and Rogers,
1996). The importance of the acidic domain for Mdm2 stability
and the data presented here could suggest that the acidic region of
Mdm2 may act as a PEST sequence.
The C-terminal fragment generated from the limited proteolysis
of the p105 precursor of NFkB has not been detected and there is a
lack of precursor–product relation between the p105 and p50
forms (Lin et al, 1998, 2000). This behaviour is also observed here
for full-length hMdm2 and the 32kDa fragment. In the case of
NFkB, these phenomena have been proposed by some authors to
be because of cotranslational processing of the protein during
synthesis (Lin et al, 1998, 2000). This model is unlikely to be
compatible with our observations since mutations near the C-
terminus of the protein (at the NoLS) impair the appearance of the
32kDa band.
Another way to explain our observations is that in normal
conditions, hMdm2 undergoes a first proteasome-dependent
cleavage within the acidic domain and that in the presence of
the nuclear export inhibitor LMB, the N-terminal portion persists,
while the C-terminus is degraded. This lack of further degradation
of the N-terminal region when nuclear export is inhibited could be
because of a direct effect of inhibition of nuclear export on the
32kDa fragment, which retains its nuclear export signal at
positions 197–211 (Roth et al, 1998). However, we have not been
able to see that the 32kDa fragment specifically accumulates in the
nuclear compartment (unpublished data) and as mentioned
before, the nuclear export mutant of hMdm2 behaves exactly as
the wild-type. LMB could also have an effect on the activity or
localisation of proteasomes. This is unlikely since we have shown
that the full-length hMdm2 is still effectively degraded in LMB-
treated cells and that the 32kDa fragment is very stable and does
not seem to be further stabilised by LMB.
Alternatively, inhibition of nuclear export by LMB could induce
a modification at the amino-terminal half of the full-length protein
and this modification could prevent the amino 32kDa fragment of
hMdm2 from complete degradation. This ‘protective’ modification
may be related to the appearance of the slower migrating form of
full-length hMdm2 with LMB. Interestingly, the PI3-kinase
inhibitor LY294002 induces the accumulation of full-length
hMdm2 and an apparently equivalent N-terminal 32kDa fragment
of hMdm2 to that seen with LMB (Menendez S, unpublished
data).
In summary, the observations presented here on the effect of
LMB on hMdm2 indicate that the degradation of hMdm2 could be
a stepwise process and therefore it can be limited in particular
circumstances.
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